title: Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
abstract: We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
authors.affiliation: Saint Louis University, St. Louis, Missouri 63110, USA. belsherb@slu.edu
authors.forename: Robert B
authors.initials: RB
authors.lastname: Belshe
authors.forename: Frances K
authors.initials: FK
authors.lastname: Newman
authors.forename: Edwin L
authors.initials: EL
authors.lastname: Anderson
authors.forename: Peter F
authors.initials: PF
authors.lastname: Wright
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Karron
authors.forename: Sharon
authors.initials: S
authors.lastname: Tollefson
authors.forename: Frederick W
authors.initials: FW
authors.lastname: Henderson
authors.forename: H Cody
authors.initials: HC
authors.lastname: Meissner
authors.forename: Shabir
authors.initials: S
authors.lastname: Madhi
authors.forename: Don
authors.initials: D
authors.lastname: Roberton
authors.forename: Helen
authors.initials: H
authors.lastname: Marshall
authors.forename: Richard
authors.initials: R
authors.lastname: Loh
authors.forename: Peter
authors.initials: P
authors.lastname: Sly
authors.forename: Brian
authors.initials: B
authors.lastname: Murphy
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Tatem
authors.forename: Valerie
authors.initials: V
authors.lastname: Randolph
authors.forename: Jill
authors.initials: J
authors.lastname: Hackell
authors.forename: William
authors.initials: W
authors.lastname: Gruber
authors.forename: Theodore F
authors.initials: TF
authors.lastname: Tsai
mesh_terms: D000281:Administration, Intranasal; D000914:Antibodies, Viral / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D022241:Parainfluenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010253:Respirovirus Infections / Q000276:immunology / Q000517:prevention & control; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D022241:Parainfluenza Vaccines; D022261:Respiratory Syncytial Virus Vaccines; D017778:Vaccines, Combined